Facial reconstruction

Search LJMU Research Online

Browse Repository | Browse E-Theses

Plasma Vascular Endothelial Growth Factor Concentration and Alveolar Nitric Oxide as Potential Predictors of Disease Progression and Mortality in Idiopathic Pulmonary Fibrosis.

Sexton, DW, Wilson, AM, Kotecha, J, Shulgina, L and Atkins, CP (2016) Plasma Vascular Endothelial Growth Factor Concentration and Alveolar Nitric Oxide as Potential Predictors of Disease Progression and Mortality in Idiopathic Pulmonary Fibrosis. Journal of Clinical Medicine, 9 (5). ISSN 2077-0383

This is the latest version of this item.

[img]
Preview
Text
Plasma Vascular EGF conc and alveolar NO as potential predictors of disease progression and mortalitiy in IPF 2016.pdf - Published Version
Available under License Creative Commons Attribution.

Download (769kB) | Preview

Abstract

BACKGROUND: Declining lung function signifies disease progression in idiopathic pulmonary fibrosis (IPF). Vascular endothelial growth factor (VEGF) concentration is associated with declining lung function in 6 and 12-month studies. Alveolar nitric oxide concentration (CANO) is increased in patients with IPF, however its significance is unclear. This study investigated whether baseline plasma VEGF concentration and CANO are associated with disease progression or mortality in IPF. METHODS: 27 IPF patients were studied (maximum follow-up 65 months). Baseline plasma VEGF concentration, CANO and pulmonary function tests (PFTs) were measured. PFTs were performed the preceding year and subsequent PFTs and data regarding mortality were collected. Disease progression was defined as one of: death, relative decrease of ≥10% in baseline forced vital capacity (FVC) % predicted, or relative decrease of ≥15% in baseline single breath diffusion capacity of carbon monoxide (TLCO-SB) % predicted. RESULTS: Plasma VEGF concentration was not associated with progression-free survival or mortality. There was a trend towards shorter time to disease progression and death with higher CANO. CANO was significantly higher in patients with previous declining versus stable lung function. CONCLUSION: The role of VEGF in IPF remains uncertain. It may be of value to further investigate CANO in IPF. KEYWORDS: alveolar nitric oxide; idiopathic pulmonary fibrosis; vascular endothelial growth factor

Item Type: Article
Uncontrolled Keywords: alveolar nitric oxide; idiopathic pulmonary fibrosis; vascular endothelial growth factor
Subjects: R Medicine > RM Therapeutics. Pharmacology
Divisions: Pharmacy & Biomolecular Sciences
Publisher: MDPI AG
Date Deposited: 30 Mar 2017 09:10
Last Modified: 04 Sep 2021 11:45
DOI or ID number: 10.3390/jcm5090080
Editors: Barnes, D
URI: https://researchonline.ljmu.ac.uk/id/eprint/6138

Available Versions of this Item

View Item View Item